All cans of Eli Lilly's The hugely popular weight reduction injection Zepbound and the diabetes drug Mounjaro at the moment are available within the US, in keeping with a To update was listed within the U.S. Food and Drug Administration's drug shortage database on Friday.
An earlier update said some doses of the treatments were still briefly supply. Some doses of Mounjaro have been briefly supply since 2022, while doses of Zepbound entered the FDA's shortage list earlier this 12 months following its U.S. approval in November.
Demand for weight reduction and diabetes drugs has exceeded supply for months, forcing Eli Lilly and its competitor Novo Nordisk billions to spice up production.
The FDA update comes at some point after Eli Lilly CEO David Ricks said Bloomberg that the shortages at Mounjaro and Zepbound would end “very soon”.
“I think we plan to finish this process today or tomorrow,” he told the outlet in an interview.
A spokesperson for Eli Lilly didn’t immediately reply to CNBC's request for comment on the FDA's update on Friday.
All doses of Novo Nordisk's diabetes injection Ozempic will probably be available within the U.S. starting Friday, the FDA said. DatabaseMeanwhile, the FDA said some doses of Novo Nordisk's weight-loss drug Wegovy were running low.
image credit : www.cnbc.com